{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T23:05:26Z","timestamp":1746486326702},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T00:00:00Z","timestamp":1395878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00115-014-4005-y","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T12:28:03Z","timestamp":1395750483000},"page":"720-726","source":"Crossref","is-referenced-by-count":7,"title":["Fumars\u00e4ure in der Therapie der Multiplen Sklerose"],"prefix":"10.1007","volume":"85","author":[{"given":"A.","family":"Haghikia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Linker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,27]]},"reference":[{"key":"4005_CR1","first-page":"103","volume":"13","author":"Schweckendiek","year":"1959","unstructured":"Schweckendiek W (1959) Treatment of psoriasis vulgaris. Med Monatsschr 13:103\u2013104","journal-title":"Med Monatsschr"},{"key":"4005_CR2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1468-1331.2006.01292.x","volume":"13","author":"Schimrigk","year":"2006","unstructured":"Schimrigk S, Brune N, Hellwig K et al (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13:604\u2013610","journal-title":"Eur J Neurol"},{"key":"4005_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.molmed.2013.03.004","volume":"19","author":"Haghikia","year":"2013","unstructured":"Haghikia A, Hohlfeld R, Gold R, Fugger L (2013) Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med 19:309\u2013319","journal-title":"Trends Mol Med"},{"key":"4005_CR4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"Linker","year":"2011","unstructured":"Linker RA, Lee DH, Ryan S et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:678\u2013692","journal-title":"Brain"},{"key":"4005_CR5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmet.2012.01.017","volume":"15","author":"Ashrafian","year":"2012","unstructured":"Ashrafian H, Czibik G, Bellahcene M et al (2012) Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab 15:361\u2013371","journal-title":"Cell Metab"},{"key":"4005_CR6","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.1830260916","volume":"26","author":"Jong","year":"1996","unstructured":"Jong R de, Bezemer AC, Zomerdijk TP et al (1996) Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 26:2067\u20132074","journal-title":"Eur J Immunol"},{"key":"4005_CR7","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","volume":"208","author":"Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Bruck J, Kellerer C et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291\u20132303","journal-title":"J Exp Med"},{"key":"4005_CR8","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","volume":"372","author":"Kappos","year":"2008","unstructured":"Kappos L, Gold R, Miller DH et al (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463\u20131472","journal-title":"Lancet"},{"key":"4005_CR9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098\u20131107","journal-title":"N Engl J Med"},{"key":"4005_CR10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087\u20131097","journal-title":"N Engl J Med"},{"key":"4005_CR11","first-page":"47","volume":"36","author":"Kita","year":"2014","unstructured":"Kita M, Fox RJ, Phillips JT et al (2014) Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler 36:47\u201352","journal-title":"Mult Scler"},{"key":"4005_CR12","first-page":"1582","volume":"35","author":"Kappos","year":"2013","unstructured":"Kappos L, Gold R, Arnold DL et al (2013) Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler 35:1582\u20131594","journal-title":"Mult Scler"},{"key":"4005_CR13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.clinthera.2013.08.009","volume":"35","author":"Sheikh","year":"2013","unstructured":"Sheikh SI, Nestorov I, Russell H et al (2013) Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther 35:1582\u20131594.e9","journal-title":"Clin Ther"},{"key":"4005_CR14","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","volume":"368","author":"Oosten","year":"2013","unstructured":"Oosten BW van, Killestein J, Barkhof F et al (2013) PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 368:1658\u20131659","journal-title":"N Engl J Med"},{"key":"4005_CR15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","volume":"368","author":"Ermis","year":"2013","unstructured":"Ermis U, Weis J, Schulz JB (2013) PML in a patient treated with fumaric acid. N Engl J Med 368:1657\u20131658","journal-title":"N Engl J Med"},{"key":"4005_CR16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMc1300283","volume":"368","author":"Sweetser","year":"2013","unstructured":"Sweetser MT, Dawson KT, Bozic C (2013) Manufacturer\u2019s response to case reports of PML. N Engl J Med 368:1659\u20131661","journal-title":"N Engl J Med"},{"key":"4005_CR17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.23863","volume":"73","author":"Lublin","year":"2013","unstructured":"Lublin FD, Cofield SS, Cutter GR et al (2013) Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 73:327\u2013340","journal-title":"Ann Neurol"},{"key":"4005_CR18","doi-asserted-by":"crossref","first-page":"e16172","DOI":"10.1371\/journal.pone.0016172","volume":"6","author":"Ellrichmann","year":"2011","unstructured":"Ellrichmann G, Petrasch-Parwez E, Lee DH et al (2011) Efficacy of fumaric acid esters in the R6\/2 and YAC128 models of Huntington\u2019s disease. PLoS One 6:e16172","journal-title":"PLoS One"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-014-4005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-014-4005-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-014-4005-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:14:57Z","timestamp":1558588497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-014-4005-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,27]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["4005"],"URL":"https:\/\/doi.org\/10.1007\/s00115-014-4005-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,27]]}}}